Effect of bariatric surgery on plasma GDF15 in humans

Maximilian Kleinert; Kirstine N Bojsen-Møller; Nils B Jørgensen; Maria S Svane; Christoffer Martinussen; Bente Kiens; Jørgen Wojtaszewski; Sten Madsbad; Erik Richter; Christoffer Clemmensen

doi:10.1152/ajpendo.00010.2019

Effect of bariatric surgery on plasma GDF15 in humans

Maximilian Kleinert, Kirstine N Bojsen-Møller, Nils B Jørgensen, Maria S Svane, Christoffer Martinussen, Bente Kiens, Jørgen Wojtaszewski, Sten Madsbad, Erik Richter, Christoffer Clemmensen

7 Citationer (Scopus)

Abstract

Bariatric surgery results in marked body weight loss and improves type 2 diabetes in most patients with obesity. The growth differentiation factor 15 (GDF15) has recently emerged as a novel satiety factor. To begin to understand whether GDF15 is involved in mediating the effects of bariatric surgery on body weight and glycemia in humans, we measured plasma GDF15 in patients with obesity (n = 25) and in patients with obesity and diabetes (n = 22) before and after Roux-en-Y gastric bypass (RYGB) surgery. GDF15 was increased 1 wk after RYGB compared with before surgery (689 ± 45 vs. 487 ± 28 pg/ml, P < 0.001) and GDF15 remained elevated at 3 mo (554 ± 37 pg/ml, P < 0.05), at 1 yr (566 ± 37 pg/ml, P < 0.05), and at 2.5–4 yr (630 ± 50 pg/ml, P < 0.001) after RYGB surgery. Both age and insulin sensitivity correlated with GDF15 before the surgery (r = 0.46, P < 0.0001 and r = 0.34, P < 0.001, respectively). These correlations disappeared at 2.5–4 yr following the surgery. Conversely, weight loss magnitude correlated with GDF15, measured 2.5–4 yr postsurgery (r = 0.21, P < 0.0055). In summary, circulating GDF15 increases and correlates with body weight loss following RYGB surgery.

Originalsprog	Engelsk
Tidsskrift	American Journal of Physiology: Endocrinology and Metabolism
Vol/bind	316
Udgave nummer	4
Sider (fra-til)	E615-E621
Antal sider	7
ISSN	0193-1849
DOI	https://doi.org/10.1152/ajpendo.00010.2019
Status	Udgivet - 2019

Emneord

Det Natur- og Biovidenskabelige Fakultet

FN’s Verdensmål

Dette resultat bidrager til følgende verdensmål

Adgang til dokumentet

10.1152/ajpendo.00010.2019

ajpendo.00010.2019Forlagets udgivne version, 2,3 MB

Citationsformater

@article{bccad5c5b15b458fabc5df184938094f,

title = "Effect of bariatric surgery on plasma GDF15 in humans",

abstract = "Bariatric surgery results in marked body weight loss and improves type 2 diabetes in most patients with obesity. The growth differentiation factor 15 (GDF15) has recently emerged as a novel satiety factor. To begin to understand whether GDF15 is involved in mediating the effects of bariatric surgery on body weight and glycemia in humans, we measured plasma GDF15 in patients with obesity (n = 25) and in patients with obesity and diabetes (n = 22) before and after Roux-en-Y gastric bypass (RYGB) surgery. GDF15 was increased 1 wk after RYGB compared with before surgery (689 ± 45 vs. 487 ± 28 pg/ml, P < 0.001) and GDF15 remained elevated at 3 mo (554 ± 37 pg/ml, P < 0.05), at 1 yr (566 ± 37 pg/ml, P < 0.05), and at 2.5–4 yr (630 ± 50 pg/ml, P < 0.001) after RYGB surgery. Both age and insulin sensitivity correlated with GDF15 before the surgery (r = 0.46, P < 0.0001 and r = 0.34, P < 0.001, respectively). These correlations disappeared at 2.5–4 yr following the surgery. Conversely, weight loss magnitude correlated with GDF15, measured 2.5–4 yr postsurgery (r = 0.21, P < 0.0055). In summary, circulating GDF15 increases and correlates with body weight loss following RYGB surgery.",

keywords = "Faculty of Science, GDF15, Bariatric surgery, Roux-en-Y gastric bypass, Obesity, Diabetes",

author = "Maximilian Kleinert and Bojsen-M{\o}ller, {Kirstine N} and J{\o}rgensen, {Nils B} and Svane, {Maria S} and Christoffer Martinussen and Bente Kiens and J{\o}rgen Wojtaszewski and Sten Madsbad and Erik Richter and Christoffer Clemmensen",

note = "CURIS 2019 NEXS 124",

year = "2019",

doi = "10.1152/ajpendo.00010.2019",

language = "English",

volume = "316",

pages = "E615--E621",

journal = "American Journal of Physiology: Endocrinology and Metabolism",

issn = "0193-1849",

publisher = "American Physiological Society",

number = "4",

}

TY - JOUR

T1 - Effect of bariatric surgery on plasma GDF15 in humans

AU - Kleinert, Maximilian

AU - Bojsen-Møller, Kirstine N

AU - Jørgensen, Nils B

AU - Svane, Maria S

AU - Martinussen, Christoffer

AU - Kiens, Bente

AU - Wojtaszewski, Jørgen

AU - Madsbad, Sten

AU - Richter, Erik

AU - Clemmensen, Christoffer

N1 - CURIS 2019 NEXS 124

PY - 2019

Y1 - 2019

N2 - Bariatric surgery results in marked body weight loss and improves type 2 diabetes in most patients with obesity. The growth differentiation factor 15 (GDF15) has recently emerged as a novel satiety factor. To begin to understand whether GDF15 is involved in mediating the effects of bariatric surgery on body weight and glycemia in humans, we measured plasma GDF15 in patients with obesity (n = 25) and in patients with obesity and diabetes (n = 22) before and after Roux-en-Y gastric bypass (RYGB) surgery. GDF15 was increased 1 wk after RYGB compared with before surgery (689 ± 45 vs. 487 ± 28 pg/ml, P < 0.001) and GDF15 remained elevated at 3 mo (554 ± 37 pg/ml, P < 0.05), at 1 yr (566 ± 37 pg/ml, P < 0.05), and at 2.5–4 yr (630 ± 50 pg/ml, P < 0.001) after RYGB surgery. Both age and insulin sensitivity correlated with GDF15 before the surgery (r = 0.46, P < 0.0001 and r = 0.34, P < 0.001, respectively). These correlations disappeared at 2.5–4 yr following the surgery. Conversely, weight loss magnitude correlated with GDF15, measured 2.5–4 yr postsurgery (r = 0.21, P < 0.0055). In summary, circulating GDF15 increases and correlates with body weight loss following RYGB surgery.

AB - Bariatric surgery results in marked body weight loss and improves type 2 diabetes in most patients with obesity. The growth differentiation factor 15 (GDF15) has recently emerged as a novel satiety factor. To begin to understand whether GDF15 is involved in mediating the effects of bariatric surgery on body weight and glycemia in humans, we measured plasma GDF15 in patients with obesity (n = 25) and in patients with obesity and diabetes (n = 22) before and after Roux-en-Y gastric bypass (RYGB) surgery. GDF15 was increased 1 wk after RYGB compared with before surgery (689 ± 45 vs. 487 ± 28 pg/ml, P < 0.001) and GDF15 remained elevated at 3 mo (554 ± 37 pg/ml, P < 0.05), at 1 yr (566 ± 37 pg/ml, P < 0.05), and at 2.5–4 yr (630 ± 50 pg/ml, P < 0.001) after RYGB surgery. Both age and insulin sensitivity correlated with GDF15 before the surgery (r = 0.46, P < 0.0001 and r = 0.34, P < 0.001, respectively). These correlations disappeared at 2.5–4 yr following the surgery. Conversely, weight loss magnitude correlated with GDF15, measured 2.5–4 yr postsurgery (r = 0.21, P < 0.0055). In summary, circulating GDF15 increases and correlates with body weight loss following RYGB surgery.

KW - Faculty of Science

KW - GDF15

KW - Bariatric surgery

KW - Roux-en-Y gastric bypass

KW - Obesity

KW - Diabetes

U2 - 10.1152/ajpendo.00010.2019

DO - 10.1152/ajpendo.00010.2019

M3 - Journal article

C2 - 30721097

SN - 0193-1849

VL - 316

SP - E615-E621

JO - American Journal of Physiology: Endocrinology and Metabolism

JF - American Journal of Physiology: Endocrinology and Metabolism

IS - 4

ER -

Effect of bariatric surgery on plasma GDF15 in humans

Abstract

Emneord

FN’s Verdensmål

Adgang til dokumentet

Fingeraftryk

Citationsformater